Market Research Logo

Hypoglycemia - Pipeline Review, H2 2018

Hypoglycemia - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H2 2018, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 6, 5 and 2 respectively.

Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Hypoglycemia - Overview
Hypoglycemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypoglycemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoglycemia - Companies Involved in Therapeutics Development
Adocia SAS
Arecor Ltd
Eiger BioPharmaceuticals Inc
Eli Lilly and Co
Heptares Therapeutics Ltd
LATITUDE Pharmaceuticals Inc
Novartis AG
Rezolute Inc
Therakind Ltd
USV Pvt Ltd
XERIS Pharmaceuticals Inc
Zealand Pharma AS
Zucara Therapeutics Inc
Hypoglycemia - Drug Profiles
dasiglucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exendin-(9-39) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3143753 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3185643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-900018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRL-2903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide 1 to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RZ-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypoglycemia - Dormant Projects
Hypoglycemia - Discontinued Products
Hypoglycemia - Product Development Milestones
Featured News & Press Releases
Jun 25, 2018: Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen
Jun 23, 2018: Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)
Jun 08, 2018: Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
May 28, 2018: Zealand Pharma reports completion of the second and pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia
Apr 11, 2018: Zealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagon
Apr 10, 2018: Data from Lilly Real-World Use Study Designed to Evaluate Moderate or Severe Hypoglycemia Treatment Published in Pediatric Diabetes Journal
Mar 26, 2018: Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia
Mar 20, 2018: Zealand Pharma's first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary objective
Feb 21, 2018: Zealand Pharma reports completion of the first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia
Feb 15, 2018: Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia
Feb 08, 2018: FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH)
Jan 19, 2018: Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half
Dec 07, 2017: Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
Nov 20, 2017: Adocia Reports Top line Results of BioChaperone Glucagon Phase 1 Study
Sep 21, 2017: JDRF Funds Zucara Therapeutics' Approach to Preventing Hypoglycemia in People with Type 1 Diabetes
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hypoglycemia, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Hypoglycemia - Pipeline by Adocia SAS, H2 2018
Hypoglycemia - Pipeline by Arecor Ltd, H2 2018
Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, H2 2018
Hypoglycemia - Pipeline by Eli Lilly and Co, H2 2018
Hypoglycemia - Pipeline by Heptares Therapeutics Ltd, H2 2018
Hypoglycemia - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2018
Hypoglycemia - Pipeline by Novartis AG, H2 2018
Hypoglycemia - Pipeline by Rezolute Inc, H2 2018
Hypoglycemia - Pipeline by Therakind Ltd, H2 2018
Hypoglycemia - Pipeline by USV Pvt Ltd, H2 2018
Hypoglycemia - Pipeline by XERIS Pharmaceuticals Inc, H2 2018
Hypoglycemia - Pipeline by Zealand Pharma AS, H2 2018
Hypoglycemia - Pipeline by Zucara Therapeutics Inc, H2 2018
Hypoglycemia - Dormant Projects, H2 2018
Hypoglycemia - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Hypoglycemia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report